Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes.

D S Loose, … , R A Marcus, D Feldman


Ketoconazole has recently been shown to interfere with steroidogenesis in patients and rat in vitro systems. In this study we attempted to elucidate the site of inhibition in the adrenal gland. Although ketoconazole impaired adrenocorticotropic hormone stimulated cyclic (c)AMP production, dibutyryl cAMP addition did not bypass the steroidogenic blockade indicating that the critical ketoconazole-inhibited step was distal to cAMP. Addition of radiolabeled substrates to isolated adrenal cells and analysis of products by high performance liquid chromatography demonstrated a ketoconazole block between deoxycorticosterone (DOC) and corticosterone. This 11-hydroxylase step is carried out by a P450-dependent mitochondrial enzyme. No restriction of progesterone or pregnenolone conversion to DOC was detected, steps carried out by non-P450-dependent microsomal enzymes. Inhibition of cholesterol conversion to pregnenolone by mitochondrial fractions indicated a second block at the side chain cleavage step, another mitochondrial P450-dependent enzyme. Adrenal malate dehydrogenase, a non-P450-dependent mitochondrial enzyme was not inhibited while renal 24-hydroxylase, a P450-dependent mitochondrial enzyme in another organ, was blocked by ketoconazole. We conclude that ketoconazole may be a general inhibitor of mitochondrial P450 enzymes. This finding suggests that patients receiving ketoconazole be monitored for side effects relevant to P450 enzyme inhibition. Further, we raise the possibility that this drug action may be beneficially exploited in situations where inhibition of steroidogenesis is a therapeutic goal.

Find the latest version:
https://jci.me/110903/pdf
Ketoconazole Blocks Adrenal Steroidogenesis by Inhibiting Cytochrome P450-dependent Enzymes

DAVID S. LOOSE, PATRICIA B. KAN, MARGARET A. HIRST, ROBERT A. MARCUS, and DAVID FELDMAN, Stanford University School of Medicine, Department of Medicine, Stanford, California 94305

ABSTRACT Ketoconazole has recently been shown to interfere with steroidogenesis in patients and rat in vitro systems. In this study we attempted to elucidate the site of inhibition in the adrenal gland. Although ketoconazole impaired adrenocorticotrophic hormone stimulated cyclic (c)AMP production, dibutyryl cAMP addition did not bypass the steroidogenic blockade indicating that the critical ketoconazole-inhibited step was distal to cAMP. Addition of radiolabeled substrates to isolated adrenal cells and analysis of products by high performance liquid chromatography demonstrated a ketoconazole block between deoxycorticosterone (DOC) and corticosterone. This 11-hydroxylase step is carried out by a P450-dependent mitochondrial enzyme. No restriction of progesterone or pregnenolone conversion to DOC was detected, steps carried out by non-P450-dependent microsomal enzymes. Inhibition of cholesterol conversion to pregnenolone by mitochondrial fractions indicated a second block at the side chain cleavage step, another mitochondrial P450-dependent enzyme. Adrenal malate dehydrogenase, a non-P450-dependent mitochondrial enzyme was not inhibited while renal 24-hydroxylase, a P450-dependent mitochondrial enzyme in another organ, was blocked by ketoconazole. We conclude that ketoconazole may be a general inhibitor of mitochondrial P450 enzymes. This finding suggests that patients receiving ketoconazole be monitored for side effects relevant to P450 enzyme inhibition. Further, we raise the possibility that this drug action may be beneficially exploited in situations where inhibition of steroidogenesis is a therapeutic goal.

INTRODUCTION

Ketoconazole has been an efficacious antimycotic agent because of its minimal toxicity and its effectiveness after oral administration against a wide range of fungal pathogens (1). However the appearance of gynecomastia in a few patients (2) was suggestive of a drug-hormone interaction. We and others recently showed that ketoconazole interfered with the production of adrenal (3) and gonadal steroids (4) both in patients and rat in vitro systems. These findings raised the possibility that ketoconazole, or a specifically designed analogue, could have additional utility as an inhibitor of steroidogenesis in the myriad clinical settings where reduction of steroid production would be useful, including Cushing's syndrome, hirsutism, and hormone-dependent cancers. We therefore pursued our studies of ketoconazole action to elucidate the step(s) in the steroidogenic pathway that were blocked by this antimycotic agent. The present paper demonstrates that ketoconazole inhibits adrenal mitochondrial P450-dependent enzymes. We detected inhibition of both the cholesterol side chain cleavage step as well as the 11-hydroxylation step. In addition, a kidney mitochondrial P450 enzyme, 25-hydroxy vitamin D-24-hydroxylase, was also blocked, suggesting that ketoconazole may have the general property of inhibiting P450-dependent enzymes. In the light of these findings additional side effects of ketoconazole relevant to P450 inhibition should be closely monitored. Moreover, we believe that studies to exploit this enzyme-blocking activity of ketoconazole in new clinical situations are now warranted.

METHODS

Adrenal preparations. Female Sprague-Dawley rats, 220–300 g, were decapitated and the adrenal glands re-
moved. Isolated adrenal cells were prepared by collagenase digestion as previously described (3). DNA was measured by the diphenylamine method (5). Rats that were ether-stressed for 10 min to raise endogenous adrenocorticotropic hormone (ACTH) were used to prepare adrenal mitochondria by the method described by Mason et al. (6).

Corticosterone and cyclic (c)AMP. Total cAMP (cells and medium combined) was extracted into 6% trichloroacetic acid, neutralized by the addition of CaCO₃ (7), and measured by radioimmunoassay (Becton, Dickinson & Co., Orangeburg, NY). Corticosterone was extracted from the medium with methylene chloride and measured by radioimmunoassay as previously described (3).

Steroidogenic studies. After 15 min of pretreatment of isolated cells or mitochondria with ketoconazole or vehicle (saline), radioactive substrates were added (0.5-1.0 μCi/ml) to begin the assay. Incubations were carried out for 5-120 min at 37°C under 95% O₂:5% CO₂. The reactions were stopped by centrifugation and radiolabeled products in the medium were extracted in 10 vol of chloroform/methanol, 2:1 (8). Following a wash with methanol/saline/chloroform, 47:50:3 (Folch wash), the organic phase was taken to dryness under nitrogen. Samples were redissolved in 70% methanol and an aliquot was injected into a Varian model 5000 high performance liquid chromatograph (HPLC) equipped with a 30 cm reverse-phase column (Varian MCH-10, Varian Associates, Inc., Palo Alto, CA). The mobile phase was methanol and water. [3H]Cholesterol (47 Ci/mmole), [3H]deoxytocosterone ([3H]DOC) (40 Ci/mmole), [3H]progesterone (51 Ci/mmole), and [14C]pregnenolone (56 mCi/mmole) were all purchased from Amersham Corp. (Arlington Heights, IL). Radioinert steroids used for standards were purchased from Steraloids, Inc., (Wilton, NH).

24-Hydroxylase activity was assessed in a cultured pig kidney cell line (LLC-PK₁) by measuring the conversion of 25-hydroxy[3H]vitamin D₃ (Amersham Corp., 20 Ci/mmole) to 24,25(OH)₂D₃ by an HPLC method (9). Adrenal mitochondrial malate dehydrogenase activity was measured by the method of Hoppel and Cooper (10).

RESULTS AND DISCUSSION

The first experiments were designed to evaluate the possibility that ketoconazole interfered with the initial steps of ACTH-stimulated corticosterone production. We reasoned that measurement of cAMP generation would allow detection of an inhibitor action at the level of the ACTH receptor, the regulatory protein or the adenylate cyclase system. As shown in Table I, ketoconazole did partially inhibit cAMP generation. However, the reduction in cAMP was disproportionately less than the ketoconazole effect to inhibit corticosterone production (3) and therefore did not seem adequate to explain the steroidogenic block. This is especially true in the light of the excess cAMP that is known to be generated in relation to that required for steroidogenesis (11).

<table>
<thead>
<tr>
<th>Condition</th>
<th>cAMP (pmol/μg DNA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal</td>
<td>1.2±0.2</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>2.6±0.8</td>
</tr>
<tr>
<td>ACTH</td>
<td>6.2±1.8</td>
</tr>
<tr>
<td>ACTH + ketoconazole</td>
<td>3.1±0.4</td>
</tr>
</tbody>
</table>

Total cAMP (cells plus medium) was measured by radioimmunoassay after 30 min of incubation in the presence of ACTH (5 ng/ml) and/or ketoconazole (5 μg/ml). Values shown are means±SE of five experiments.

To ascertain whether the cAMP inhibition played a role in the ketoconazole blockade of corticosterone production, we performed a dibutyl cAMP (Bt₂cAMP) "bypass" experiment. As shown in Table II, ketoconazole inhibited corticosterone production despite Bt₂cAMP addition. The inability of Bt₂cAMP to bypass the ketoconazole blockade indicated that the impairment in steroidogenesis was distal to the cAMP production step.

We next sequentially evaluated the three major distal steroidogenic enzyme steps by making additions of the relevant radiolabeled substrates to isolated adrenal cells and analyzing the products by HPLC (Fig. 1). With [3H]DOC as substrate, ketoconazole inhibition of 11-hydroxylase activity was observed. Using [3H]progesterone as substrate, conversion to DOC was demonstrated showing substantial 21-hydroxylase activity; accumulation of DOC confirmed the 11-hydroxylase block shown previously. Similary, with [14C]pregnenolone as substrate, conversion to progesterone and DOC but not corticosterone was detected demonstrating the presence of 3-β-hydroxysteroid dehy-

<table>
<thead>
<tr>
<th>Condition</th>
<th>Corticosterone (ng/μg DNA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal</td>
<td>50±14</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>23±9</td>
</tr>
<tr>
<td>Bt₂cAMP</td>
<td>136±5</td>
</tr>
<tr>
<td>Bt₂cAMP + ketoconazole</td>
<td>26±11</td>
</tr>
</tbody>
</table>

Corticosterone production was measured by radioimmunoassay after 60 min of incubation in the presence of Bt₂cAMP (1.0 mM) and/or ketoconazole (5 μg/ml). Values shown are means±SE of four experiments.

---

1 Abbreviations used in this paper: ACTH, adrenocorticotropic hormone; Bt₂cAMP, dibutyl cAMP; cAMP, cyclic AMP; DOC, deoxycorticosterone; HPLC, high performance liquid chromatograph(y).
isotopically labeled adrenal cells, in which we have shown that an increase in cortisol production is linearly related to the dose of ketoconazole administered. The adrenal cells were isolated from patients taking ketoconazole as monotherapy for the treatment of Cushing's syndrome, and the results were compared with those from control patients not taking ketoconazole.

The adrenal cells were incubated for 24 hours with increasing concentrations of ketoconazole (0.1, 1.0, and 10.0 µg/ml) and the cortisol production was measured. As shown in the graph, the cortisol production increased linearly with increasing concentrations of ketoconazole. The cortisol production in the group receiving 10.0 µg/ml of ketoconazole was significantly higher than that in the control group.

In conclusion, the results of this study suggest that ketoconazole is an effective and safe treatment for Cushing's syndrome. The study highlights the potential role of ketoconazole in the management of Cushing's syndrome and provides a basis for further research in this area.

Ketoconazole Blocks Adrenal Steroidogenesis

70% increasing linearly to 100% between 15 and 17 min, and continuing at 100% for the remaining elution period. The standards were run in the same system: B, corticosterone; DOC, deoxycorticosterone; Prog, progesterone; Preg, pregnenolone.

Ketoconazole Blocks Adrenal Steroidogenesis

1497
The postulated mechanism of action of ketoconazole, inhibition of fungal sterol synthesis, is presumed to occur at the 14-demethylation step in the conversion of lanosterol to ergosterol (13). Since this mixed function oxidase may also be P450 dependent, it perhaps should not be surprising that similar mammalian enzymes are also affected. In the light of the current findings, what is most striking is the lack of toxicity
of ketoconazole noted thus far. This may relate to the pharmacokinetics of ketoconazole and the requirement for near peak concentrations of drug to inhibit the enzymes.

The information developed here regarding the actions of ketoconazole on mammalian P450-dependent enzymes indicates the need for continued careful monitoring of patients receiving this drug to detect specific side effects involving these very important enzyme systems. This is especially pertinent if the dose and/or frequency of ketoconazole administration are increased. On the other hand, we believe that this action of ketoconazole, to impair steroid hormone synthesizing activity, may be usefully exploited in those clinical settings where inhibition of steroidogenesis would be a beneficial therapeutic goal.

ACKNOWLEDGMENT
This work was supported, in part by National Institutes of Health grant GM 28825.

REFERENCES